NCT05819307 (STARFLI) is a clinical trial of OCT/FLIM in Retinal Disease, sponsored by Insel Gruppe AG, University Hospital Bern.

Who is sponsoring NCT05819307?

NCT05819307 is sponsored by Insel Gruppe AG, University Hospital Bern.

What drugs are being tested in NCT05819307?

Interventions in NCT05819307: OCT/FLIM.

What condition does NCT05819307 study?

NCT05819307 studies Retinal Disease.

Is NCT05819307 still recruiting?

NCT05819307 is currently status unknown. Last updated 19 April 2023.

Last reviewed 2023-04-19 · How we verify

NCT05819307: STARFLI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Structural Imaging Assisted Retinal Fluorescence Lifetime Imager (STARFLI)

Status unknown Last updated 19 April 2023

What this trial tests

trial testing OCT/FLIM in Retinal Disease in 70 participants. Status unknown.

Timeline

1 May 2023

Primary endpoint
31 December 2023

1 May 2024

Quick facts

Lead sponsor	Insel Gruppe AG, University Hospital Bern
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	70
Start date	1 May 2023
Primary completion	31 December 2023
Estimated completion	1 May 2024
Sites	1 location across Switzerland

Drugs / interventions tested

OCT/FLIM

Conditions studied

Retinal Disease — all drugs for Retinal Disease →

Sponsor

Insel Gruppe AG, University Hospital Bern

Who can join

Adults 18 to 120, any sex, with Retinal Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the feasibility of a combined OCT/FLIM device

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Retinal Disease

Currently open trials in the same condition.

NCT07149740 — Data Gathering for A10900 · recruiting
NCT06852963 — A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Parti · Phase 1, PHASE2 · recruiting
NCT05699096 — Perfluorooctyl Bromide Which Empowers the Liquid to Flat the Detached Retina and Displace the Underneath Fluids Anterior · recruiting
NCT06289452 — Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked Retinoschisis · EARLY_PHASE1 · active not recruiting
NCT06520410 — Safety and Efficacy of 18 mm Short Vitrectomy Probe for Pediatric Vitreoretinal Surgeries · Phase 4 · recruiting

Other Insel Gruppe AG, University Hospital Bern trials

Trials by the same sponsor.

NCT06546384 — GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease · NA · not yet recruiting
NCT07524049 — Giving Children a Voice in Paediatric Anaesthesia · not yet recruiting
NCT07415668 — Motor Eloquent Navigated Transcranial Magnetic Stimulation for Radiosurgery Planning · NA · not yet recruiting
NCT07478536 — Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial) · not yet recruiting
NCT07201506 — Real-Time Intracardiac Echocardiography for Ventricular Arrhythmia Ablation · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05819307 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Insel Gruppe AG, University Hospital Bern
Last refreshed: 19 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05819307.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing